VORHealthcare · BiotechnologyThe 9 Wall Street analysts covering Vor Biopharma, Inc. hold a median 12-month price target of $40 — +111.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 21 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Vor Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (84): Sales and profits are climbing, and climbing faster than before.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VOR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +111.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | William Blair | Initiates | Outperform | — |
| 12 Aug 2026 | Wedbush | Maintains | Neutral | $18 → $27 |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $31 |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | Wedbush | Maintains | Neutral | $15 → $18 |
| 14 May 2026 | Wedbush | Maintains | Neutral | — |
| 15 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Mar 2026 | Wedbush | Maintains | Neutral | — |
| 30 Mar 2026 | Jefferies | Initiates | Buy | — |
| 19 Mar 2026 | Wells Fargo | Initiates | Overweight | — |
| 9 Jan 2026 | Citigroup | Initiates | Buy | — |
| 19 Dec 2025 | JP Morgan | Maintains | Overweight | — |
| 17 Dec 2025 | TD Cowen | Initiates | Buy | — |
| 9 Dec 2025 | JP Morgan | Initiates | Overweight | — |
| 25 Nov 2025 | Wedbush | Assumes | Neutral | $9.00 |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Oct 2025 | Baird | Upgrade | Outperform | — |
| 14 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 June 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VOR appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Vor Biopharma, Inc. returned −28.5% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 97% of US stocks
Cheaper than 81% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vor Biopharma, Inc. has a market value of $1.1B and an enterprise value of $662.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: $627.8M.
Free cash flow in the twelve months to 30 June 2026: −$140.8M.
Trailing P/E: 0.1×; forward P/E: −5.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Vor Biopharma, Inc. employs 76 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vor Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vor Bio said its experimental drug slowed the loss of kidney function in a late-stage study.
Why it matters — The reported late-stage study result is relevant to VOR watchers tracking the company's experimental drug research.
GlobeNewsWire reports that telitacicept preserved kidney function through two years in the Phase 3 TELIGAN trial in IgA nephropathy. Annualized eGFR slope was -0.6 versus -5.7 mL/min/1.73 m²/year for placebo, a treatment difference of 5.1.
Why it matters — This report concerns another company’s clinical-trial results and provides no stated connection to Vor Biopharma.
On October 1, 2026, Vor Bio's Compensation Committee granted stock options for 59,250 shares and restricted stock units for 12,550 shares of common stock to nine newly hired employees as inducements to employment, under the company's 2023 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters — This reveals the terms of equity inducements offered to newly hired employees, which could slightly inform shareholders about potential dilution and the company's hiring activity.
Vor Bio announced new post hoc results from a Phase 3 trial in China conducted by collaborator RemeGen evaluating telitacicept in generalized myasthenia gravis. The data show deep and durable minimal symptom expression through 48 weeks, with over 94% of participants achieving meaningful improvement and most MSE events sustained.
Why it matters — The promising long-term efficacy data from its collaborator's Phase 3 trial could strengthen the case for telitacicept as a treatment for autoimmune disease, a key focus of VOR's pipeline.
Vor Biopharma is advancing telitacitecept globally, leveraging strong Chinese clinical evidence and a $514.5M liquidity position. Its global Phase 3 trials in myasthenia gravis and Sjögren's are fully enrolled or underway, with topline MG data expected in H1 2027, though it faces competitive pressure from argenx, Amgen, and Novartis.
Why it matters — VOR watchers would care because the article highlights the company's strong funding and progress on late-stage trials that could define its commercial path.
The 9 Wall Street analysts covering Vor Biopharma, Inc. have a median 12-month price target of $40, with estimates ranging from $27 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Vor Biopharma, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vor Biopharma, Inc. 21 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Oct 2026, Vor Biopharma, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +111.2% from the last close, and Ticker Nerd's factor model ranks Vor Biopharma, Inc. 21 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vor Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $50 over the next 12 months.
Vor Biopharma, Inc. returned -28.5% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases.
The most recent item we track (Reuters, 22 Oct 2026): "Vor Bio says its experimental drug slowed loss of kidney function in late-stage study". Vor Bio said its experimental drug slowed the loss of kidney function in a late-stage study.
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions. The company’s current development and commercialization efforts center on autoimmune indications such as generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s disease, and IgA nephropathy. Vor Biopharma works on advancing this therapy through clinical development and broader market access, positioning its platform within the specialized immunology and biopharmaceutical segments. Headquartered in Cambridge, Massachusetts, Vor Biopharma plays a role in the market by addressing serious chronic diseases with targeted biologic treatment approaches.
CEO Dr. Jean-Paul Kress M.D. · 76 employees · United States · https://www.vorbio.com
